Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in moderate-to-severe scalp psoriasis
NCT05478499Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of deucravacitinib in psoriasis, sponsored by Bristol Myers Squibb. Started Oct 2022; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05478499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478499.